Maria Karlgren
Senior Lecturer/Associate Professor at Institutionen för farmaci; Läkemedelsformulering
- Telephone:
- +46 18 471 41 49
- Mobile phone:
- +46 73 469 76 21
- E-mail:
- maria.karlgren@farmaci.uu.se
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala - Postal address:
- Box 580
751 23 UPPSALA
Download contact information for Maria Karlgren at Institutionen för farmaci; Läkemedelsformulering
More information is available to staff who log in.
Short presentation
My research interests are in drug absorption, distribution, metabolism and excretion (ADME) with a focus on drug metabolizing enzymes, drug transport proteins, drug permeability, transport-metabolism interplay, drug-drug interactions, and on the development of predictive models for studying such processes. My current research program is focused on in vitro models for predicting drug delivery to the human brain.
Publications
Recent publications
- Integration of Mass Spectrometry Imaging and Machine Learning Visualizes Region-Specific Age-Induced and Drug-Target Metabolic Perturbations in the Brain (2021)
- Expanding the Efflux In Vitro Assay Toolbox (2021)
- Acamprosate Is a Substrate of the Human Organic Anion Transporter (OAT) 1 without OAT3 Inhibitory Properties (2020)
- The Permeation of Acamprosate Is Predominantly Caused by Paracellular Diffusion across Caco-2 Cell Monolayers (2019)
- CRISPR-Cas9 (2018)
All publications
Articles
- Integration of Mass Spectrometry Imaging and Machine Learning Visualizes Region-Specific Age-Induced and Drug-Target Metabolic Perturbations in the Brain (2021)
- Expanding the Efflux In Vitro Assay Toolbox (2021)
- Acamprosate Is a Substrate of the Human Organic Anion Transporter (OAT) 1 without OAT3 Inhibitory Properties (2020)
- The Permeation of Acamprosate Is Predominantly Caused by Paracellular Diffusion across Caco-2 Cell Monolayers (2019)
- CRISPR-Cas9 (2018)
- An imidazole based H-Phe-Phe-NH2 peptidomimetic with anti-allodynic effect in spared nerve injury mice (2018)
- A mass spectrometry imaging approach for investigating how drug-drug interactions influence drug blood-brain barrier permeability (2018)
- A CRISPR-Cas9 Generated MDCK Cell Line Expressing Human MDR1 Without Endogenous Canine MDR1 (cABCB1) (2017)
- Intracellular drug bioavailability (2017)
- Impact of drug transporters on intracellular unbound drug concentrations (2016)
- Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells (2016)
- Complete Knockout of Endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9 (2016)
- Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes (2016)
- Mechanistic modeling of hepatic pitavastatin disposition (2016)
- Comparative proteome analysis of human liver tissue and isolated hepatocytes (2016)
- Global Membrane Protein Analysis Of The Human Liver (2015)
- Comparative Proteomic Analysis of Human Liver Tissue and Isolated Hepatocytes with a Focus on Proteins Determining Drug Exposure (2015)
- Hepatic Uptake of Atorvastatin (2014)
- Combined in Vitro-in Vivo Approach To Assess the Hepatobiliary Disposition of a Novel Oral Thrombin Inhibitor (2013)
- An Integrated in Vitro Model for Simultaneous Assessment of Drug Uptake, Metabolism, and Efflux (2013)
- In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug-Drug Interactions (2012)
- Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs) (2012)
- Uptake mechanism of ochratoxin A and citrinin through human liver (2010)
- Interaction of 140 orally administered drugs with the liver-specific organic anion transporter OATP1B1 (SLCO1B1) (2010)
- Specific and general inhibitors of the three hepatic organic anion transporters OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3) and OATP2B1 (SLCO2B1) (2010)
- Integrated cell models for prediction of drug transport and drug metabolism in the human hepatocyte (2010)
- Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment (2010)
- The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer (2009)
- A pharmaceutical quality by design approach to develop high-performance nanoparticles for magnetic hyperthermia
- Imaging age-induced perturbations of mitochondrial function, neurotransmission and lipid signaling in specific brain regions
Chapters
